Lipoplus (Omega-3-Acid Triglycerides, Soya-Bean Oil Refined, Triglycerides, Medium Chain)

Lipoplus is used in clinical situations where intravenous lipid provision is required to support nutrition and fatty‑acid balance.

• Parenteral nutrition in patients unable to receive enteral feeding: supplies calories and essential fatty acids intravenously.
• Prevention of essential fatty acid deficiency: maintains adequate levels of omega‑3 and omega‑6 fatty acids.
• Critical illness or postoperative care: supports metabolic demands when oral intake is insufficient.

• Lipoplus delivers a mixture of omega‑3‑acid triglycerides, refined soybean oil triglycerides, and medium‑chain triglycerides directly into the bloodstream. These lipids are hydrolyzed to free fatty acids, providing an immediate energy source, incorporating into cell membranes, and supplying essential fatty acids that cannot be synthesized by the body, thereby supporting cellular function and modulating inflammatory pathways.

Lipoplus may be associated with a range of adverse reactions following intravenous administration.

Common Side Effects

• Hypertriglyceridemia: elevated serum triglyceride levels.
• Fever or chills during infusion.
• Infusion site reactions such as erythema or pain.
• Mild elevation of liver enzymes.
• Electrolyte disturbances, particularly phosphate.
• Transient increase in bilirubin.

Serious or Rare Side Effects

• Fat overload syndrome: severe hyperlipidemia with organ dysfunction.
• Anaphylactic or severe allergic reaction.
• Pulmonary embolism or fat embolism.
• Thrombocytopenia or coagulopathy.
• Significant hepatic dysfunction or cholestasis.
• Infection risk related to lipid medium supporting microbial growth.

When using Lipoplus, clinicians should observe several safety measures to minimize risks.

• Assess triglyceride levels: monitor serum triglycerides before and during therapy.
• Check liver function: regularly evaluate hepatic enzymes and bilirubin.
• Avoid in patients with known hypersensitivity to soy, fish, or lipid emulsions.
• Use caution in severe hyperlipidemia or pancreatitis.
• Limit infusion rate: follow recommended guidelines to prevent fat overload.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lipoplus can interact with other therapies, requiring careful management.

Major Interactions (Avoid)

• Concomitant use with other lipid emulsions: risk of cumulative fat overload.
• High‑dose propofol infusion: additive lipid load may exacerbate hypertriglyceridemia.
• Certain cytotoxic chemotherapy agents: may increase hepatic toxicity.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin): lipid infusion may affect INR stability.
• Diuretics: monitor electrolytes, especially phosphate.
• Insulin therapy: lipid infusion can influence glucose control, requiring dose adjustments.